EPISODE · Dec 3, 2025 · 11 MIN
GenSight Biologics' Novel Gene Therapy Approach to Reversing Blindness from Genetic Eye Disorders
from WTR Healthcare Happenings · host Joe Brunetto
On the latest WTR Healthcare Happenings podcast episode, we welcomed Jan Eryk Umiastowski, CFO of GenSight Biologics (Euronext Paris: SIGHT), a late clinical-stage biopharma company based in Paris, France, primarily focused on developing and commercializing novel disease-modifying gene therapies aimed at reversing vision loss from severe neurodegenerative retinal diseases. He discusses GenSight's development pipeline, what's unique about the company's approach to gene therapy and upcoming target milestones.
What this episode covers
On the latest WTR Healthcare Happenings podcast episode, we welcomed Jan Eryk Umiastowski, CFO of GenSight Biologics (Euronext Paris: SIGHT), a late clinical-stage biopharma company based in Paris, France, primarily focused on developing and commercializing novel disease-modifying gene therapies aimed at reversing vision loss from severe neurodegenerative retinal diseases. He discusses GenSight's development pipeline, what's unique about the company's approach to gene therapy and upcomi...
NOW PLAYING
GenSight Biologics' Novel Gene Therapy Approach to Reversing Blindness from Genetic Eye Disorders
No transcript for this episode yet
Similar Episodes
No similar episodes found.